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Abstract
Uterine Arterial Embolization: Classification of Leiomyomas to Determine Predictors of
Response
Trushar J. Patel, Sharon D'Heureux, and Michael J. Tal. Section of Interventional Radiology, Department of
Diagnostic Radiology, Yale University, School of Medicine, New Haven, CT

The purpose of this study is to determine features of uterine leiomyoma on Magnetic
Resonance Imaging (MRI) that identify predictors of response to Uterine Arterial
Embolization (UAE). MRI images were obtained before and after UAE in 35 women.
These images were analyzed for uterine and fibroid size changes along with fibroid border
characteristics and location for a total of 73 fibroids. Fibroids were classified as either
smooth or lobulated based on border appearance on MR imaging to determine any
differences in mean fibroid volume reduction post-embolization. The mean decrease in
fibroid volume from pre-embolization to post-embolization was 48.1% ± 28.6 % (SD) (P <
0.001). No statistical difference was detected in the mean volume reduction between
lobulated and smooth fibroids, 40.6% ± 23.1% (SD) and 50.9% ± 30.2% (SD) respectively,
with a confidence interval [-25.1, 4.6, SEM 7.5, Df 71], single factor ANOVA
(F[1,71]=1.88, Fcrit=3.98, p=0.17). However, some difference was detected in the failure
rate of lobulated versus smooth fibroids to embolization, 5% and 9.4% respectively,
ANOVA (F [1, 71]= 0.37, Fcrit= 3.98, p > 0.1), albeit at low statistical power. Also no
difference was detected in mean fibroid volume reduction between intramural, submucosal,
and subserosal fibroids. Thus, we introduced a novel characteristic by which to classify
uterine fibroids based upon border appearance on MR imaging.
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Chapter 1
INTRODUCTION
Background / Incidence
Uterine leiomyomas, also known as fibroids, are benign tumors arising from the smooth
muscle of the uterus and contain various amounts of interstitial fibrotic tissue. Although the
genesis of such fibroids is uncertain, it is thought that a multi-factorial process involving
hormone dysregulation along with genetic factors may play a large role in the formation of
uterine fibroids. Gonadal steroids are thought to play a large role in the growth of fibroids,
however the formation of fibroids is not necessarily linked to these hormones.
While the true incidence of fibroids is unknown due to the high prevalence of
asymptomatic patients, the reported incidence is generally between 20% and 40% with a
much higher incidence of nearly 50% in women of African-American heritage. In African
American women, the estimated cumulative incidence by age 50 is greater than 80%, while
in Caucasian women the estimated cumulative incidence by age 50 is around 70% (1).
Most women with symptomatic fibroids are between 30 and 40, with few fibroids
described in adolescent women.

Risk Factors
Women of African American descent are two to three times as likely to develop fibroids as
Caucasian women. In addition to increased incidence, African American women are likely
to be younger at the time of presentation with greater severity of disease related to higher
uterine volumes and increased bleeding (2). Other risk factors for fibroid formation include
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nuliparity (3, 4) and family history of fibroids (5). Factors that have been shown to reduce
risk for fibroid formation include parity, and smoking, through an unknown mechanism
(3).

Clinical Presentation
As mentioned previously, a large number of women with uterine fibroids are
asymptomatic. Fibroids that are symptomatic can manifest with a variety of symptoms.
While the clinical presentation of fibroids differs in each woman, the most common
presenting symptom is that of menorrhagia or metrorrhagia. Symptoms are typically related
to the size, location, and direction of growth of the fibroids, and fall into three broad
categories, uterine bleeding, pelvic pressure, and disturbances in reproduction. As
mentioned uterine bleeding is typically menorrhagia or metrorrhagia and can result in other
secondary symptoms related to anemia, such as fatigue or depression among others.
Typically increased bleeding occurs with submucosal fibroids due to an increased
endometrial surface and a resultant larger bleeding area (6). Symptoms related to pelvic
pressure vary based on location, with fibroids in the anterior lower uterine segment
typically responsible for symptoms of urinary frequency from compression of the bladder.
Posterior fibroids may be responsible for symptoms of constipation due to pressure on the
rectum. Pain is also a common symptom related to increased pelvic pressure and can often
be associated with a low grade fever, tenderness, and elevated white blood cell count.
Fibroids may also be responsible for increased complications during pregnancy. Women
with fibroids during pregnancy may experience an increased risk of abruptio placentae,
premature labor, miscarriage, and breech presentation at birth (7, 8).
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Medical Management
Medical therapy is not the mainstay of treatment and is primarily used for relief of
symptoms or as a bridging treatment prior to surgery. Currently several pharmacotherapies
exist which may provide temporary relief of symptoms. However, discontinuation of
medical therapy often results in a rapid return of symptoms. The current mainstay of
medical treatment involves the use of gonadotropin releasing hormone agonists as a
hormone suppressive therapy. The gonadotropin releasing hormone agonists act to
reproduce a pharmacological state of menopause by initially increasing the release of
gonadotropins followed by a downregulation leading to a hypogonadal state (9). In most
cases, treatment with gonadotropin releasing hormone agonists results in a reduction in
uterine bleeding and a return to baseline of hematologic labs. Treatment also reduces
fibroid size in most cases and can effectively manage symptoms of pelvic discomfort (10).
Common side effects with gonadotropin releasing hormone agonists include osteoporosis,
hot flashes, vaginal dryness, and transient frontal headaches (11). Reports of decreased
bone density have also been reported leading to osteoporosis (10).
While the use of gonadotropin releasing hormone agonists do not constitute an effective
primary therapy, their use prior to surgery as an adjunct therapy has considerable benefit in
certain cases (11). In women undergoing myomectomy for fibroids, the use of
gonadotropin release hormone agonists may permit a smaller incision, or for women
undergoing hysterectomy, may allow vaginal hysterectomy due to a reduction in uterine
and fibroid size. In women with considerable blood loss secondary to fibroids, the use of
gonadotropin releasing hormone agonist may also allow for a return in hematocrit over
time alleviating the need for blood transfusion (12).
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Surgical Management
As mentioned, surgery is the mainstay of treatment for uterine fibroids. Surgery is indicated
in cases of symptomatic uterine fibroids not adequately controlled by more conservative
treatment or in cases where a high suspicion of malignancy exists. Other indications for
surgical management include growth of uterine fibroids following menopause, infertility
related to tubal obstruction, or recurrent pregnancy loss (13). Several options exist for
surgical management including total hysterectomy, myomectomy, and several newer
procedures, such as uterine artery occlusion, and uterine artery embolization.

Hysterectomy
Currently in the United States more than 600,000 hysterectomies are performed per year
(14). Nearly a quarter to a third of the hysterectomies performed in the United States are
performed for symptomatic uterine fibroids (15). The advantage of classic hysterectomy
includes relief from symptomatic uterine fibroids, as well as eliminating the chance of
recurrence. A recent study following 1,299 women found that over 90% of the women
noticed improved quality of life, decreased symptoms, and decreased depression two years
after hysterectomy (16). Hysterectomy is also indicated over other surgical procedures
when a high suspicion of malignancy exists or in patients with extensive fibroids not
amenable to myomectomy. In the absence of these factors, issues concerning uterine
conservation and future child-bearing should be addressed when considering between the
available options.
While the overall mortality rate with hysterectomy is quite low, this procedure is not
without complications. Complications that are seen most often include incontinence,
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vaginal vault prolapse, and risk of premature ovarian failure (17). Incontinence secondary
to urinary tract injuries during surgery often occur most commonly in cases where uterine
fibroids extend into the broad ligament, compress the bladder, or extend deep into the
pelvis (13).

Myomectomy
Myomectomy is a surgical alternative to hysterectomy and allows for the preservation of
the uterus along with the possibility of future pregnancies. In cases involving a solitary
pedunculated fibroid, myomectomy is also the preferred surgical treatment. Although
myomectomy is an effective therapy for menorrhagia and pelvic pressure, the disadvantage
of this procedure is the significant risk that fibroids will re-occur. While hysterectomy
eliminates the reoccurrence of fibroids, according to a recent meta-analysis study, fibroids
may reoccur in nearly 20-50% of cases 5 years after myomectomy (18).

Hysteroscopic Myomectomy
Submucosal fibroids can be removed by a procedure known as hysteroscopic
myomectomy. This procedure utilizes the submucosal location of fibroids to enter the
cervix without an incision using a specialized scope that can cut and coagulate tissue from
within the cavity. Compared to abdominal myomectomy, hysteroscopic myomectomy
offers several advantages including the use of local anesthetic versus general anesthesia.
Hysteroscopic myomectomy is also an outpatient procedure with a short recovery period.
As described in a large prospective study of 156 women followed over 9 months after
hysteroscopic myomectomy, fewer than 16% of women underwent a subsequent procedure
for recurrent menorrhagia (19). For women considering pregnancy, hysteroscopic
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myomectomy offers excellent fertility rates with a very low complication rate. In one study
of 23 patients with associated infertility, pregnancy was achieved in eight cases following
hysterscopic myomectomy (20).

Laparoscopic Uterine Artery Occlusion
Uterine artery occlusion is performed as a laparoscopic procedure in which the uterine
arteries supplying the dominant fibroids are occluded. The advantage of this procedure
compared to uterine artery embolization is that this approach allows for thorough and direct
examination of the pelvis and avoids the use of foreign material such as embolization
agents into the body. However a disadvantage of this procedure over uterine artery
embolization is that it is still a surgical approach requiring general anesthesia.

Uterine Artery Embolization
Uterine artery embolization (UAE) was first reported as a successful treatment for lifethreatening gynecologic bleeding in 1979 (21, 22). Since this initial successful intervention,
UAE has been reported as a successful procedure in the control of bleeding from a variety
of different sources including tumors and traumatic pelvic injuries (23-25). The first use of
UAE for symptomatic uterine fibroids was reported in 1994 (26) and given the relative lack
of complications and relatively high success rates reported in initial cases, research into
uterine fibroid embolization (UFE) as a possible treatment for symptomatic uterine fibroids
continued (27-29).

Indication for Embolization
Compared to hysterectomy and medical treatment, uterine fibroid embolization is a
relatively new procedure. To date, no absolute criteria exist for the indication to perform
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UFE. From the literature the most common indications to perform UFE include contraindications to surgery and recurrent fibroids following alternative therapies such as
myomectomy (30). In the management of uterine fibroids prior to considering UFE, a
thorough gynecological workup must be performed in order to consider relevant
differential diagnoses such as endometrial polyps, leiomyosarcoma, focal contractions of
the myometrium, and extrauterine findings (e.g., ovarian tumors), all of which are absolute
contraindications for UFE. In addition to a thorough gynecological workup, further
imaging studies should be obtained prior to performing UFE to provide more detailed
information regarding type, size, and exact number of fibroids. MRI is the preferred
imaging modality allowing a detailed overview of the pelvic anatomy along with the ability
to differentiate carcinomas of the endometrium, adenomyosis, and different types of
fibroids (31, 32).
It is unclear whether adenomyosis represents an absolute contra-indication to UFE, several
reports describe circumstances where patients with adenomyosis do not improve
symptomatically after UFE (33, 34). However, a single study in the literature reports
improvement of clinical symptoms in adenomyosis after UFE (35). Other relative contraindications for UFE include non-growing fibroids in menopausal women or in
postmenopausal women with atypical bleeding, along with pedunculated or very large
fibroids extending above the level of the umbilicus (30). Absolute contra-indications for
UFE in addition to those listed above include fibroids with a very thin pedicle, infection of
the genital tract, and contra-indications to contrast dyes.
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Technique of Embolization
Uterine fibroid embolization (UFE) involves the placement of a catheter and the injection
of embolization agent into the dominant artery or arteries that supply the uterine fibroids.
Typically access is obtained through a femoral access route, then traversing the internal
iliac artery to the uterine artery. Most fibroids due to the dual supply of the uterus from
both uterine arteries are also supplied by both uterine arteries, necessitating embolization of
both uterine arteries (36, 37). However, arteriography before embolization is necessary to
exclude any additional supplying arteries or aberrant arterial malformations.
In general UFE takes advantage of the fact that uterine fibroids are typically supplied by
high flow arterial branches of the uterine arteries. This is in stark contrast to the normal
myometrium, which tends to be supplied by low flow arterial branches of the uterine
arteries. The difference in flow rates of the arteries supplying the fibroids versus the normal
myometrium allows placement of the catheter delivering the embolization agent relatively
proximal in the uterine artery with delivery of the embolization agent somewhat selectively
to the branches supplying the fibroid or fibroids given their high flow state.
The choice of embolization agent is highly user dependent with choices ranging from
polyvinyl alcohol particles, gelfoam, and stainless steel coils, to tris-acryl gelatin
microspheres. To date there exists no consensus on the most effective embolization agent,
however a recent study noted that the use of spherical polyvinyl alcohol particles led to a
particularly high rate of failed fibroid tumor infarction (38). Additionally, no consensus
exists on the ideal size of embolizing particles, with reports suggesting success with
particle sizes ranging from 150-500 μm to 500-710 μm (39-41). Some reports have

9
suggested that smaller embolization particles may result in a greater overall decrease in size
of fibroids, however an increase in the rate of complications notably ovarian and cervical
ischemia (40).

Results of Embolization
Following uterine fibroid embolization, technical success rates vary from 85% to 100% in
most reported studies (42-44). Technical success is characterized by occlusion or marked
reduction in the blood flow of both uterine arteries, and not by reduction in size of fibroids,
or reduction of symptoms. Clinical success on the other hand involves parameters that
include the reduction in size of fibroids, reduction of patient symptoms, and patient
satisfaction. The range of overall reduction in dominant fibroid size seems to vary between
42% - 83%, with the largest reduction in overall fibroid size occurring during the first six
months and an additional decrease over the next six months (27, 45, 46). Overall uterus
size reduction post UFE varies from 43% - 58% (27, 45-47).
In contrast to reduction in fibroid volumes, relief of patient symptoms occurs with much
higher frequency with a range of 86% - 94% and elimination of abnormal uterine bleeding
in 88% - 96% of cases (30, 46-48). One such study, a randomized control trial comparing
UFE to hysterectomy found the success rate of controlling abnormal bleeding after UFE to
be 88.9% (17) consistent with another previous smaller randomized study (44).

Pregnancy after UFE
While UFE does preserve the uterus in contrast to hysterectomy, there is much debate as to
the safety of UFE in those women desiring future pregnancies. Currently in the literature
there is only limited data regarding the outcome of pregnancies after UFE. While several
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studies do report full term pregnancies following UFE, it may be at the cost of higher prepartum and post-partum complications (49-51). In a meta-analysis study of previously
published cases of pregnancy following UFE for symptomatic fibroids, a 32% rate of
spontaneous abortion was reported compared to a rate of 10-15% in the general population.
A 22% rate of malpresentation was reported in post-UFE pregnancies vs. 5% in the general
population, 22% rate of premature delivery vs. 5-10%, a 65% cesarean delivery rate vs.
22% in the general population, and a 9% rate of postpartum hemorrhage vs. 4-6% in the
general population (52). The authors report a possibility for the increased malpresentation
rate due to the presence of residual leiomyomata. In a recent study comparing the outcomes
of pregnancy post UFE versus laparoscopic myomectomy, the rates of preterm delivery,
malpresentation, postpartum hemorrhage, and spontaneous abortion were slightly higher in
pregnancies following UFE, however these increased rates were not statistically significant
(53).

Complications of Embolization
Overall most case reports and studies suggest that UFE has a low complication rate and
remains safe as an alternative to hysterectomy and myomectomy. A randomized control
clinical trial comparing UFE to hysterectomy found intra-procedural complication rates to
be similar between UFE and hysterectomy, 25% versus 20% respectively (44). However
within the UFE group all events were categorized as minor complications consisting of
arterial spasm, uterine artery dissection, or gluteal artery perforation. Whereas the
complications within the hysterectomy group were all categorized as major complications
with patients either needing transfusion or having had vesical fissure. Post-procedural
complication rates between the two groups were 72% for UFE and 45% for patients who
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underwent hysterectomy again with the majority of complications in UFE categorized as
minor complications versus most of the complications being categorized as moderate and
major complications in the hysterectomy group.
A large prospective 400 patient study followed UFE patients over 3 months for all adverse
events and complications (54). These events and complications were then categorized
according to the Society of Cardiovascular and Interventional Radiology complication
classes, A through F, with severity of complications increasing from minor complications,
class A, to major, severe complications comprising class F. Minor complications listed as
class A and B occurred in 10.5% of patients with the most common complication listed as
allergic reaction. Other complications within this category included fibroid passage,
hematoma, urinary tract infection, femoral nerve injury, urinary retention, deep venous
thrombosis, and clostridium difficile infection. Class C complications were encountered in
2.5% of patients. These included four hospitalizations for pain control, four for fibroid
passage, and two hospitalizations for endometritis. Of the five patients (1.25%) that had
class D complications, the first patient was diagnosed with a pulmonary embolus, the
second patient developed bilateral iliac artery thrombosis that was treated with
thrombolytic therapy. The third patient was hospitalized for a uterine infection 10 weeks
after embolization secondary to fibroid tissue passage, while the fourth patient had a similar
infection requiring hysteroscopic removal of the fibroid tissue. The fifth patient had
extensive bleeding secondary to fibroid passage 4 months following embolization, which
required a hysterectomy after dilation and curettage failed to control the bleeding. There
were no reported class E or class F complications within this study and no reported deaths.
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While not reported in the previously mentioned study, another important, however rare,
complication includes ovarian failure after UFE. Reported rates of ovarian failure after
UFE range from 1-2% (43) and are likely secondary to unintended embolization of the
ovaries via utero-ovarian anastomoses (55).
Death is also a complication not readily considered given the very low rates of occurrence.
Currently there are three reported deaths documented in the literature following UFE, two
of these cases involving pulmonary embolus, and the last death as a result of infection (56,
57).
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Chapter 2

STATEMENT OF PURPOSE
The purpose of this study is to first classify uterine fibroids based on MR image border
appearance of either the smooth or lobulated variety. Currently no such system exists to
categorize uterine fibroids based on appearance. The utility of this categorization is to add
another variable by which to analyze the factors that may play an important role in
determining fibroids that are more responsive to uterine fibroid embolization (UFE). While
no good criteria exist for the evaluation of fibroids amenable to treatment by embolization,
our goal was to evaluate factors of fibroid location, and border appearance to determine if
any of these criteria could be used as predictive factors for responsiveness to UFE. Using
existing data classifying outcomes of patients undergoing UFE, we will attempt to correlate
our categorization of uterine fibroid appearance on MRI to outcomes and MR images postembolization.
Our hypothesis is that a difference exists between the two categories of uterine fibroids
seen on MRI to the rate of responsiveness following UFE and that fibroids characterized as
lobulated respond much better to embolization than fibroids characterized as smooth in
border appearance. While no previous literature exists characterizing fibroids based on
smooth versus lobulated border criteria, there exists some literature describing variances in
fibroid signal intensity based on differing pathology. Our hypothesis stems from the
possibility that fibroids characterized as either smooth or lobulated may exhibit varying
pathology and thus respond differently to emobolization.
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Specific Aims
1. Evaluate pre-embolization MR images of patients with uterine leiomyomas and
characterize the uterine leiomyoma based on border appearance as well as location.
2. Evaluate pre-embolization and post-embolization MR images to determine
outcomes data based on uterine and leiomyoma volume changes.
3. Correlate the categorization of uterine leiomyoma with outcomes data to determine
if border characteristics play a role in predicting success in uterine fibroid
embolization.
4. Analyze data concerning location of uterine leiomyoma to determine what role if
any location plays in overall response to uterine fibroid embolization.
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Chapter 3

MATERIALS AND METHODS
This study consists of women evaluated for evidence of uterine fibroids and referred to the
Yale Interventional Radiology group. Two hundred women were treated with uterine
fibroid embolization (UFE) for symptomatic fibroids and enrolled in an already HIC
approved study looking at other outcomes data for embolization.
MRI images were obtained before and after UAE in 35 women. These images were
analyzed for uterine and fibroid size changes along with fibroid border characteristics and
location for a total of 73 fibroids.

Embolization
An experience angiographer (MJT) performed bilateral UFE in each patient. A variety of
embolization agents were used and recorded for each case, with the dominant embolization
agent being polyvinyl alcohol particles. The institutional review board gave approval for
the entire study, and each patient gave written informed consent. Patients received preprocedural MR images prior to UFE. Patients were seen in clinic and evaluated 6 months
post-operatively for follow-up. MR images were obtained at this time to observe any
change in fibroid and uterine size.

Image Evaluation
Two readers (TP and SD) independently analyzed MR images for each UFE patient. Preprocedural images were used and each reader was given T1 and T2 weighted and
gadolinium enhanced composite images of the uterus and uterine fibroids. Both readers
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were blinded to outcome and post-procedural MR images of each case. Within each image,
T2 fat saturated images were primarily used to ascertain border criteria of each fibroid.
Fibroids measured to be <3 cm in any diameter were excluded from this study. For each
fibroid >3cm, the border was described as either smooth or lobulated based on images that
were defined as standards for each category (see Figure 1). Results were compared and any
discrepancies in results were shown to an independent third reader (MJT) for analysis and
categorization. Each fibroid was also evaluated for separate criteria including location and
size. The size of each fibroid was measured both in the pre-procedural MR image and in
the follow-up MR image post-procedure. The degree of enhancement in the postprocedural MR image was also evaluated for each fibroid. The dimensions of the uterus
were also measure for each pre-procedural MR image and post-procedural MR image.
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Figure 1. T2 fat saturated, midsagittal MR Images. Images are
references for determination and categorization of uterine
leiomyoma into smooth (A, B) and lobulated (C, D) based on border
appearance.
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Data Analysis
The data gathered from each image were placed into an existing database containing dates
of pre and post – procedural films along with embolization agent used. The volume for
each fibroid was calculated using the equation for a sphere or prolate ellipse (length *
width * height * 0.523). The volume of each uterus was also determined using a prolate
ellipse equation (length * width * height * 0.523) for each pre-procedural MR image and
post-procedural MR image. The absolute volume change and percentage change for each
uterus and fibroid was determined with a determination of averages between the fibroids
categorized as either smooth or lobulated. Using a statistical analysis program (SAS) the
absolute and percentage volume changes were subjected to an Analysis of Variance
(ANOVA) test to determine p-values. Also inter-patient variance was determined using a
fisher t-test.

Contribution
My contributions to the project were primarily focused on analyzing and interpreting both
the pre-operative and post-operative MR images for each patient along with much of the
statistical analysis performed. Out of the nearly 200 uterine fibroid embolizations (UFE), I
was present for only a fraction of the cases seen in follow-up clinic. Specifically using an
already established database containing patient names and dates of embolization along with
other data points, I analyzed each MR image for every patient listed in the database. I
categorized each dominant fibroid as to whether the border was either smooth or lobulated
and merged this information with the existing database. Working with the MR imaging
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fellow, we were able to measure and mark the location of each fibroid in the pre-operative
and post-operative images. I entered this data as well into the database and tabulated the
calculated fibroid and uterine volumes. After all of the imaging data were collected, I
reformatted the data to be used in a statistical modeling program (SAS) and subsequently
ran the date through multiple variances of the t-test and ANOVA test.
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Chapter 4
RESULTS
MRI images were obtained before and after UAE in 35 women. These images were
analyzed for uterine and fibroid size changes along with fibroid border characteristics and
location for a total of 73 fibroids.

Volume Changes
From the analysis of pre-embolization MR images from 35 women, the average uterine
volume was 656.6 cm3 ± 590.6 cm3 (SD). The average fibroid volume (n= 73) prior to
embolization was 125.6 cm3 ± 203.9 cm3 (SD). After embolization, the average uterine
volume was 356.7 cm3 ± 305.2 cm3 (SD). This resulted in an average decrease of 35.7% ±
24.9% (SD) from pre-embolization uterine volume to post-embolization volume (P <
0.001). The mean fibroid volume post-embolization was 57.6 cm3 ± 85.8 cm3 (SD),
resulting in an average decrease of 48.1% ± 28.6 % (SD) from pre- to post-embolization
volume (P < 0.001). The mean elapsed time between pre-embolization and postembolization MR images was approximately 38 weeks and 5 days.

Prognostic Features
Two categories of prognostic features were analyzed, border appearance and location.
Border appearance was described as either smooth or lobulated. Approximately 29.3% of
fibroids were lobulated (n= 22) with an average volume of 237.5 cm3 ± 203.9 cm3 (SD)
pre-embolization and an average volume of 129.4 cm3 ± 101.2 cm3 (SD) postembolization. Fibroids categorized as smooth comprised 70.7% (n= 53) of the total fibroids
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with an average volume of 83.4 cm3 ± 189.1 cm3 (SD) pre-embolization and an average
volume of 30.5 cm3 ± 70.0 cm3 (SD) post-embolization. The average volume change in
lobular fibroids from pre-embolization volume to post-embolization volume was 108.1
cm3 ± 143.0 cm3 (SD) resulting in a reduction of 40.6% ± 23.1% (SD). In fibroids
characterized as smooth, the average volume change from pre-embolization to postembolization was 52.9 cm3 ± 164.9 cm3 (SD) resulting in a reduction of 50.9% ± 30.2%
(SD).

Mean Reduction in Fibroid Volume
70.00
60.00

% Reduction

50.00
Lobular
40.00

Smooth

30.00
20.00
10.00
0.00
Fibroid Category

Figure 2. Graph shows a comparison of mean reduction in fibroid
volume before and after embolization between lobulated and
smooth fibroids. Error bars indicate 95% confidence intervals for
each group.

The calculated confidence interval for the mean change in volume between lobulated and
smooth fibroids is [-25.1, 4.6, SEM 7.5, Df 71]. Since this interval includes zero, the
possibility that both mean volume changes may be equal exists, and we cannot conclude
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that there is statistical difference between the mean volume changes in both groups. Single
factor ANOVA demonstrated no appreciable difference of mean volume change between
the two groups (F [1,71]= 1.88, Fcrit= 3.98, p= 0.17). However if we define failure of
embolization as no reduction or increase of fibroid volume from pre-embolization to postembolization, there was a single failure within the lobulated fibroids for a failure rate of
5%. Within fibroids categorized as smooth, there were a total of five failures for a failure
rate of 9.4%. Single factor ANOVA demonstrated some difference between the two groups
when looking at failure rate, however with low statistical power (F [1, 71]= 0.37, Fcrit=
3.98, p= 0.26).

Box Plot % Reduction in Fibroid Volume
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Figure 3. Graph illustrates a comparison of pre-embolization and
post-embolization fibroid volume reduction in fibroids between
smooth and lobulated fibroids. Box plots show median (middle line
of box), first quartile (bottom line of box), third quartile (top line of
box), minimum values (lower whisker), and maximum values (upper
whisker).
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Similar results were obtained when looking at location as a prognostic indicator. While
there was some difference between the groups, there was little statistical power to indicate
with certainty that location is a prognostic factor in determining outcome after
embolization. Approximately 64.4% of fibroids were intramural (n= 47), 12.3%
submucosal (n= 9), and 23.3% subserosal (n= 17). The mean pre-embolization volume for
intramural fibroids was 155.1 cm3 ± 218.7 cm3 (SD) with a mean post-embolization
volume of 65.2 cm3 ± 86.0 cm3 (SD). The mean pre-embolization volume for submucosal
fibroids was 127.2 cm3 ± 276.5 cm3 (SD) with a mean post-embolization volume of 71.6
cm3 ± 138.7 cm3 (SD). The mean pre-embolization volume for subserosal fibroids was
43.3 cm3 ± 41.0 cm3 (SD) with a mean post-embolization volume of 29.1 cm3 ± 32.8 cm3
(SD). The average change in volume from pre-embolization volume to post-embolization
volume in each of the groups was 89.8 cm3 ± 186.2 cm3 (SD), 55.6 cm3 ± 148.5 cm3
(SD), 14.3 cm3 ± 12.0 cm3 (SD) respectively for intramural, submucosal, and subserosal
fibroids for a reduction in volume of 51.6% ± 30.2% (SD) in intramural fibroids, 43.9% ±
29.4% (SD) in submucosal fibroids, and 40.6% ± 22.9% (SD) in subserosal fibroids. Single
factor ANOVA demonstrated no appreciable difference of mean volume change between
the three groups (F [2,70]= 1.04, Fcrit= 3.13, p > 0.2).
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Figure 4. Graph illustrates a comparison of pre-embolization and
post-embolization fibroid volume reduction in fibroids of different
locations. Box plots show median (middle line of box), first quartile
(bottom line of box), third quartile (top line of box), minimum
values (lower whisker), and maximum values (upper whisker).

Subserosal
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DISCUSSION
Discussion
Findings from this study do not clearly demonstrate a significant difference in volume
reduction between fibroids categorized as either lobulated or smooth on MR imaging.
While some minor differences are noted, the low statistical power does not allow us to
draw a distinct conclusion. Similarly, findings from this study do not suggest a significant
difference in volume reduction of fibroids post-embolization based upon fibroid location.
Our study does suggest some minor difference when looking at overall embolization failure
rate rather than volume changes between smooth and lobulated fibroids, albeit again with
low statistical power.

Uterine volumes
Clearly the relative change in uterine volume relative to fibroid type is not of statistical
significance. Uterine volume as a measurement of embolization success is an inaccurate
predictor of overall success given that uterine volume changes in accordance to a variety of
factors. When measuring uterine volumes post-embolization, relative changes in fibroids
seen on the pre-procedural MR image are measured along with fibroids that may not have
been seen at the time of the initial MR image that have since increased in size. Thus overall
uterine volume is not an accurate predictor of embolization success and although useful
cannot be used to ascertain predictive factors that determine outcome. The usefulness of
uterine volume changes in determining the differences between smooth and lobulated
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fibroids is also confounded by the fact that in some of the patients, multiple fibroids of both
varieties were present, rendering the uterine volume change useless in those patients.

Fibroid volumes
While uterine volume change is not an accurate assessment of success following
embolization, individual fibroid volume changes are an accurate measurement of response
following embolization. Previous studies investigating predictive factors correlating to
embolization success have used a variety of findings to measure success including
ultrasonography and improvement in physical symptoms. MR provides an improved
accuracy over ultrasonography and a much simpler measure of success over improvement
in physical symptoms. The value of improvement in clinical symptoms is certainly
important following embolization, however there is such variability in assessing such
criteria that it becomes very difficult to ascertain a true measure of success given the
subjective nature of obtaining patient history. Several studies have validated the use of MR
characteristics as a measurement of success following embolization (58).
There was a significant reduction in mean uterine fibroid volumes in our study. This result
is consistent with the 45%-65% range of mean uterine fibroid volume reduction reported in
other studies (33). Our results showed that there was little difference in the overall
reduction of fibroid volumes between smooth and lobulated fibroids, with little statistical
power suggesting a strong difference in response. It is unclear why on average fibroids of
the lobulated variety were nearly three times the size of the smooth variety. Not all large
fibroids were of the lobulated variety and not all small fibroids were of the smooth variety.
Whether this size difference confounds our data regarding the overall percentage change in
fibroids post-embolization is also unclear. There has been some speculation that larger
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uterine volumes and larger fibroid volumes may exhibit varying responses to embolization
secondary to embolization particle distribution (59). Also a greater number of embolization
particles may be required for larger fibroids, rather than current protocols that do not titrate
embolization particles based on size of uterus or fibroids.

Predictive Factors
Despite the relative lack of difference in fibroid volume change between the two groups,
when looking at failure defined as an increase in fibroid size after embolization there was a
trend towards a difference between the two groups. Only one fibroid within the lobulated
category increased in size post-embolization representing a 5% failure rate. This is in
contrast to the fibroids categorized as smooth which had a near 10% failure rate, with five
fibroids showing an increase in size after embolization. It is hard to draw a definite
conclusion based on this result in the absence of correlation based on overall mean fibroid
volume change between the two groups, however it does suggest some fundamental
difference between fibroids classified as either smooth or lobulated. Whether this
difference extends to the level of pathology is unclear and certainly warrants further
investigation. Previous studies suggest different cellular pathology for fibroids exhibiting
varying signal intensity levels on MR, with high signal intensity fibroids composed of
compact smooth muscle cells compared to fibroids exhibiting decreased signal intensity
due to uniform smooth muscle cells with various amounts of intervening collagen (60, 61).
Perhaps lobulated fibroids exhibit similar disparities on pathology compared to fibroids
with a smooth border appearance, to date there exists no literature mentioning any
characteristics of either smooth or lobulated fibroids.
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While the main focus of this study was the categorization of fibroids based on MR image
appearance, the data allow for other factors to be independently analyzed. The location and
type of each fibroid was noted for use as a possible predictor of outcome postembolization. While not thoroughly characterized, some studies have concluded that
submucosal fibroids have a strong correlation to positive outcomes as compared to
intramural and subserosal fibroids (59). Our study found no real correlation between
location of fibroid and change in fibroid volume after embolization.

Limitations of the study
While every step was taken to ensure that the data gathered were accurate and not
misrepresented, every study has certain limitations that must be considered when drawing a
conclusion regarding data presented within the study. Certainly as is true for many studies,
sample size plays a large role in the power of a study. In our case, while the sample size is
quite large, there is still not enough data regarding the non-responders to embolization.
Given that success rates of embolization in regards to overall reduction of fibroid size vary
from 42% to 83% (27, 45, 46), and in our study roughly 90%, the total sample size of cases
in which fibroids did not respond to embolization is very low. Naturally, increasing the
sample size and thus increasing the number of cases in which failure occurred would add
statistical power to the study to analyze factors that play a role in determining nonresponders to embolization.
Several other potential sources of error play a role in determining the conclusions that can
be drawn from this study. One large source of error comes from the subjective nature of
determining the characteristic of the fibroid border. Since categorizing fibroids as either
lobulated or smooth is not a readily quantifiable measurement, this introduces a source
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potential error. While an attempt to minimize this error was made by having two
independent readers categorize each fibroid and a third reader to rectify any discrepancy,
this cannot be ruled out as a potential source of error. Another limitation of this study is the
inability to factor many of the other variables that may have played a role in the outcomes
of both fibroid and uterine volumes after embolization. These factors include the relative
location of each fibroid as well as the presence of adenomyosis. As mentioned the role of
embolization in patients with adenomyosis is unclear. Several studies report no
improvement in patients with adenomyosis (33, 34), whereas a single recent study does
report improvement after embolization (35). It is unclear what role adenomyosis plays in
the reduction of individual fibroid and uterine size post-embolization. In our study we were
unable to distinguish between patients with adenomyosis from those without adenomyosis.
Another factor that was not accounted for in this study was the choice of embolization
agent used for each patient. While the dominant embolization agent was polyvinyl alcohol
particles, the choice of embolization agent and resultant outcome based on agent used was
not determined. However based upon the single patient variance studies, the variability of
embolization agent used would not play a role.
Lastly, while the majority of fibroids decrease in size the greatest over the first 6 months
post-embolization (46), not all fibroids decrease at the same rate. Ideally follow-up images
would be obtained at identical times post-embolization for each patient and at multiple time
points, however in reality this is not technically feasible given the variability in availability
of imaging resources and the incapacity to obtain multiple MR images for a large patient
sample. In our study there was some variability between each patient in the length of time
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that images were obtained post-embolization. This variability could have played some role
in the overall measurement of reduction in both fibroid and uterine volumes.
Despite the potential limitations of this study, the data provide some interesting conclusions
in the response of fibroids to embolization and warrant further investigation into the
potential differences that contribute to the appearance on MR imaging of fibroids as either
smooth or lobulated and what differences, if any, there are in response to embolization.

Conclusion
Currently uterine fibroid embolization (UFE) is a viable treatment option for women
experiencing symptomatic uterine fibroids not wanting to undergo hysterectomy. While the
overall success rate of UFE is very good, there exist a small percentage of women who do
not benefit from UFE. However, to date no reliable criteria exist regarding the prediction of
outcomes amongst women undergoing UAE for uterine fibroids. Size of fibroids has been
in some studies implicated as a predictive factor (43, 47), however this finding has not been
consistent throughout studies looking at predictive factors (30, 58). A predictive factor that
would classify uterine leiomyomas as either likely responders or non-responders would be
of great use in determining proper pre-embolization candidates and likely increase the
overall response rate in UAE as well as overall patient satisfaction.
We introduced a novel characteristic by which to classify uterine fibroids based upon
border appearance on MR imaging in the hopes of elucidating what role, if any, border
appearance has on outcomes following embolization. Although we were not able to show a
significant difference in volume reduction between those fibroids categorized as either
lobulated or smooth, we were able to note an albeit small difference in embolization failure
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rates between smooth and lobulated fibroids. Further, our analysis did not reveal any
difference based upon fibroid location in overall volume reduction after embolization.
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